Spectrum Pharmaceuticals Inc (SPPI.OQ)
8.36USD
4:00pm EDT
$-0.08 (-0.95%)
$8.44
$8.49
$8.52
$8.32
195,638
273,328
$14.34
$6.93
About
Overall
| Beta: | 1.33 |
| Market Cap (Mil.): | $506.63 |
| Shares Outstanding (Mil.): | 60.03 |
| Dividend: | 0.15 |
| Yield (%): | -- |
Financials
| SPPI.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 12.09 | 47.13 | 37.76 |
| EPS (TTM): | 0.70 | -- | -- |
| ROI: | 14.27 | -2.58 | 18.76 |
| ROE: | 17.27 | -2.66 | 19.59 |
Spectrum shares plunge as hospitals switch to cheaper colon cancer treatment
- Shares of Spectrum Pharmaceuticals Inc fell as much as 38 percent on Wednesday after the company forecast a steep drop in full-year revenue as hospitals increasingly opt for a generic colon cancer treatment over its biggest-selling drug, Fusilev.
Spectrum shares plunge as hospitals switch to cheaper colon cancer treatment
March 13 - Shares of Spectrum Pharmaceuticals Inc fell as much as 38 percent on Wednesday after the company forecast a steep drop in full-year revenue as hospitals increasingly opt for a generic colon cancer treatment over its biggest-selling drug, Fusilev.
BRIEF-Spectrum Pharma shares down 40 pct premarket
NEW YORK, March 13 - Spectrum Pharmaceuticals Inc : * Shares down 40 percent in premarket trading
Generics seen halving Spectrum Pharma's full year Fusilev sales
- Spectrum Pharmaceuticals forecast a steep drop in full-year sales as it expects uptake of its biggest-selling product, colon cancer drug Fusilev, to significantly decline as cheaper generics re-enter the market.
Competitors
| Price | Change | |
|---|---|---|
| Ardana plc (ARA.L) | 6.50p | 0.00 |
| Neurocrine Biosciences, Inc. (NBIX.OQ) | $14.63 | +0.64 |
| AstraZeneca plc (AZN.L) | 3,334.00p | -1.00 |
| Amgen, Inc. (AMGN.OQ) | $109.45 | +1.16 |
| Bayer AG (BAYGn.DE) | €89.43 | +2.08 |
| Bayer AG (BAYE.F) | -- | -- |
| Bioniche Life Sciences (BNC.TO) | $0.32 | +0.01 |
| Eli Lilly & Co. (LLY.N) | $53.50 | +0.39 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Genentech, Inc. (DNA.N) | -- | -- |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: S&P Capital IQ Factual Report
|
$127.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

